Liquidia Technologies, Inc. (LQDA)
Stock Price:
$4.50 USD
-0.06 (-1.21%)
Updated Oct 26, 2020 2:32 PM EDT - Market open
Key Info
| Market Cap |
169.69M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-56.62M |
| Shares Out |
37.75M |
| EPS (ttm) |
-2.36 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$4.50 |
| Previous Close |
$4.55 |
| Change ($) |
-0.06 |
| Change (%) |
-1.21% |
| Day's Open |
4.59 |
| Day's Range |
4.44 - 4.71 |
| Day's Volume |
578,392 |
| 52-Week Range |
2.65 - 12.10 |
More Stats
| Market Cap |
169.69M |
| Enterprise Value |
166.87M |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.75M |
| Float |
22.74M |
| EPS (basic) |
-2.45 |
| EPS (diluted) |
-2.36 |
| FCF / Share |
-1.93 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.98M |
| Short Ratio |
6.67 |
| Short % of Float |
8.72% |
| Beta |
0.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
19.20 |
| Revenue |
n/a |
| Operating Income |
-55.63M |
| Net Income |
-56.62M |
| Free Cash Flow |
-54.92M |
| Net Cash |
2.82M |
| Net Cash / Share |
0.07 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-69.44% |
| ROE |
-276.46% |
| ROIC |
-269.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.00*
(144.72% upside)
Low
6.00
Current: $4.50
High
20.00
Target: 11.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 8.07 | 2.71 | 7.26 | 13.22 |
| Revenue Growth | 198.2% | -62.7% | -45.08% | - |
| Gross Profit | 7.26 | 2.59 | 6.94 | 12.30 |
| Operating Income | -46.82 | -34.87 | -28.03 | -15.86 |
| Net Income | -47.58 | -53.14 | -29.15 | -15.93 |
| Shares Outstanding | 18.48 | 7.16 | 0.56 | 0.44 |
| Earnings Per Share | -2.59 | -7.51 | -51.78 | -36.42 |
| Operating Cash Flow | -48.28 | -31.83 | -24.29 | -13.95 |
| Capital Expenditures | -1.85 | -0.87 | -2.54 | -2.89 |
| Free Cash Flow | -50.13 | -32.70 | -26.83 | -16.83 |
| Cash & Equivalents | 55.80 | 39.53 | 3.42 | 1.44 |
| Total Debt | 24.42 | 12.77 | 22.15 | 8.68 |
| Net Cash / Debt | 31.38 | 26.76 | -18.73 | -7.24 |
| Assets | 68.84 | 49.42 | 14.84 | 8.49 |
| Liabilities | 33.89 | 30.73 | 48.54 | 26.73 |
| Book Value | 34.95 | 18.69 | -33.69 | -18.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Liquidia Technologies, Inc. |
| Country |
United States |
| Employees |
64 |
| CEO |
Neal F. Fowler |
Stock Information
| Ticker Symbol |
LQDA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LQDA |
| IPO Date |
July 26, 2018 |
Description
Liquidia Technologies, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of novel products which utilize PRINT technology to transform the lives of patients. Its lead product candidate is LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials for the treatment of pulmonary arterial hypertension. The company also develops LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreement with the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.